Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Employees

3,943

Sector

Pharmaceuticals

Calendar

07-18 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-07-11	66.60 €	-0.37%	133,967
25-07-10	66.85 €	+1.83%	221,243
25-07-09	65.65 €	0.00%	393,891
25-07-08	65.65 €	+3.55%	307,083
25-07-07	63.40 €	+0.48%	149,917

Delayed Quote Nasdaq Helsinki, July 11, 2025 at 12:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

66.60EUR

Average target price

58.50EUR

Spread / Average Target

-12.16%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Helsinki Other stock markets 12:00:00 2025-07-11 EDT			5-day change	1st Jan Change
66.60 ^EUR	-0.37%		+5.55%	+55.68%

07-09	Orion raises outlook for 2025	RE
07-09	Orion Upgrades FY25 Net Sales, Operating Profit Outlook	MT

Capitalization	9.36B 10.94B 8.72B 8.11B 14.98B 939B 16.65B 104B 39.93B 440B 41.04B 40.2B 1,613B	P/E ratio 2025 *	25.6x	P/E ratio 2026 *	17.6x
Enterprise value	9.4B 10.99B 8.76B 8.14B 15.05B 943B 16.72B 105B 40.12B 442B 41.23B 40.38B 1,620B	EV / Sales 2025 *	5.6x	EV / Sales 2026 *	4.66x
Free-Float	89.32%	Yield 2025 *	2.58%	Yield 2026 *	2.78%

Orion raises outlook for 2025	07-09	RE
Orion Upgrades FY25 Net Sales, Operating Profit Outlook	07-09	MT
Orion Raises Forecasts for 2025	07-09	FW
Orion Oyj Upgrades Earnings Guidance for Full-Year 2025	07-09	CI
Orion Corporation Recommends Third Indication for Darolutamide for Patients with Advanced Prostate Cancer	06-20	CI
Bayer, Orion's Prostate Cancer Treatment Recommended for EU Approval in Third Indication	06-20	MT
CHMP Recommends Third Indication For Darolutamide For Patients With Advanced Prostate Cancer	06-20	RE
Orion Extend Research, Licensing Deal for Antibody-drug Conjugates with Glykos Finland	06-17	MT
Orion, Glykos Announce Extension Of Research Collaboration, Licensing Agreement	06-17	RE
Orion and Glykos Announce the Extension of Their Research Collaboration and Licensing Agreement for the Development of Next-Generation ADCs	06-17	CI
US FDA Approves New Indication for Bayer, Orion's Prostate Cancer Treatment	06-03	MT
U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer	06-03	CI
Orion, Shilpa Medicare Enter Commercial Deal for Albumin Product in Europe	05-23	MT

Carnegie Group Upgrades Orion to Buy, Lifts PT	04-24	MT
OP Corporate Bank raises Orion to increase (decrease), target price 59 euros - BN	04-24	FW
Carnegie upgrades Orion to buy (hold), target price 57 euro (55) - BN	04-24	FW
SEB upgrades Orion to Buy (Hold), target price EUR 57 - BN	04-24	FW
Carnegie Downgrades Orion to Hold, Reduces PT	04-11	MT

Orion Oyj Stock

Equities

ORNBV

FI0009014377

Pharmaceuticals

Valuation: Orion Oyj

Chart: Orion Oyj

Latest news: Orion Oyj

Last Transcript: Orion Oyj

Analysts' recommendations: Orion Oyj

Press Releases: Orion Oyj

News in other languages: Orion Oyj

Quotes and Performance

Course Extremes

Managers and Directors: Orion Oyj

ETFs: Orion Oyj

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Inside information: Orion upgrades full-year outlook for 2025	07-09	GL
Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025	07-04	GL
141,959 Orion Corporation A shares converted into B shares	06-23	GL
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer	06-20	GL
Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs	06-17	GL

Faute de carotte, le bâton fait son retour	07-08
Avis d'analystes du jour : nouveaux suivis sur Accor et Galderma, ArgenX relevé et Arkema dégradé	07-08
Les actions en mouvement : Une journée de plus pour la défense	05-21
Les Actions en Mouvement : Kering, Dassault Systèmes… la bourse brûle ses vieilles idoles et met le cap sur la Suisse	04-24
En bourse, le yoyo continue	04-11

1 day	-0.37%
1 week	+5.55%
Current month	+4.31%
1 month	+5.80%
3 months	+38.92%
6 months	+47.57%
Current year	+55.68%

1 week	62.7	67.7
1 month	61.7	67.7
Current year	42.8	67.7
1 year	39.39	67.7
3 years	31.86	67.7
5 years	31.86	67.7
10 years	22.57	67.7

Manager	Title	Age	Since
Aino Anna Liisa Hurme CEO	Chief Executive Officer	58	2022-10-31
René Lindell DFI	Director of Finance/CFO	49	2024-04-30
Juhani Kankaanpaa COO	Chief Operating Officer	-	2021-12-31

Director	Title	Age	Since
Eija Ronkainen BRD	Director/Board Member	59	2016-03-21
Ari Tapio Lehtoranta BRD	Director/Board Member	62	2017-03-21
Hilpi Rautelin BRD	Director/Board Member	64	2017-03-21

Name	Weight	AuM	1st Jan change
XACT NORDIC HIGH DIVIDEND LOW VOLATILITY UCITS ETF - SEK	2.96%	806 M€	+8.43%	-
SELIGSON & CO OMX HELSINKI 25 UCITS ETF - EUR	2.87%	478 M€	+15.60%	-
OSSIAM WORLD ESG MACHINE LEARNING UCITS ETF 1A - EUR	0.52%	0 M€	-.--%	-
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.35%	1,022 M€	+19.74%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ORION OYJ	-0.37%	+5.55%	+61.69%	+49.23%	10.94B
ELI LILLY AND COMPANY	+0.30%	+1.58%	-15.11%	+139.53%	712B
JOHNSON & JOHNSON	-0.50%	+0.57%	+4.81%	-12.03%	378B
ABBVIE INC.	-1.31%	+1.67%	+13.27%	+25.60%	340B
NOVO NORDISK A/S	-3.64%	-2.74%	-54.62%	+8.25%	305B
ROCHE HOLDING AG	-2.36%	-1.23%	+1.86%	-21.34%	259B
NOVARTIS AG	-3.00%	-1.93%	-3.07%	+15.94%	237B
ASTRAZENECA PLC	-1.66%	+1.10%	-13.64%	-6.31%	219B
MERCK & CO., INC.	-0.79%	+3.00%	-35.36%	-11.60%	209B
AMGEN INC.	-1.70%	-1.00%	-9.17%	+19.17%	159B
Average	-1.36%	+1.05%	-4.93%	+20.64%	282.8B
Weighted average by Cap.	-1.25%	+0.66%	-11.50%	+36.79%

	2025 *	2026 *
Net sales	1.68B 1.96B 1.56B 1.45B 2.69B 168B 2.99B 18.73B 7.16B 78.83B 7.36B 7.21B 289B	1.97B 2.31B 1.84B 1.71B 3.16B 198B 3.51B 22.04B 8.43B 92.78B 8.66B 8.48B 340B
Net income	366M 429M 341M 318M 587M 36.78B 652M 4.09B 1.56B 17.22B 1.61B 1.57B 63.16B	534M 624M 497M 463M 855M 53.57B 950M 5.96B 2.28B 25.08B 2.34B 2.29B 92B
Net Debt	44.11M 51.58M 41.09M 38.21M 70.61M 4.43B 78.47M 492M 188M 2.07B 193M 189M 7.6B	-145M -169M -135M -125M -232M -14.52B -257M -1.62B -618M -6.8B -635M -622M -24.94B